Stockscreener 앱 받기
0.655
0.80%
0.0052
전일 마감가:
$0.6498
열려 있는:
$0.641
하루 거래량:
308.85K
Relative Volume:
0.64
시가총액:
$54.17M
수익:
$38.70M
순이익/손실:
$-117.88M
주가수익비율:
-0.3853
EPS:
-1.7
순현금흐름:
$-92.84M
1주 성능:
+5.48%
1개월 성능:
-14.09%
6개월 성능:
-33.97%
1년 성능:
-54.20%
1일 변동 폭
$0.6279
$0.6924
1주일 범위
$0.5842
$0.6954
52주 변동 폭
$0.4471
$1.6399
Adicet Bio Inc Stock (ACET) Company Profile
명칭
Adicet Bio Inc
전화
617-482-2333
주소
131 DARTMOUTH STREET, BOSTON
ACET을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACET
Adicet Bio Inc
|
0.655 | 54.10M | 38.70M | -117.88M | -92.84M | -1.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Adicet Bio Inc Stock (ACET) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-30 | 재개 | Guggenheim | Buy |
| 2024-09-11 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-06-27 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-06-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-03-31 | 개시 | SMBC Nikko | Outperform |
| 2022-03-08 | 개시 | Truist | Buy |
| 2022-03-04 | 개시 | Jefferies | Buy |
| 2021-05-18 | 개시 | BTIG Research | Buy |
| 2021-04-23 | 개시 | H.C. Wainwright | Buy |
| 2021-04-14 | 개시 | Canaccord Genuity | Buy |
| 2021-04-08 | 개시 | Guggenheim | Buy |
| 2020-11-04 | 개시 | B. Riley Securities | Buy |
| 2020-10-27 | 개시 | JMP Securities | Mkt Outperform |
| 2020-10-16 | 개시 | Wedbush | Outperform |
모두보기
Adicet Bio Inc 주식(ACET)의 최신 뉴스
Will Adicet Bio Inc. benefit from sector rotationJuly 2025 Patterns & Verified Entry Point Signals - newsyoung.net
Recovery Signals Appearing in Adicet Bio Inc. Charts2025 Breakouts & Breakdowns & Capital Efficiency Focused Strategies - beatles.ru
MaxCyte Signs Platform License Agreement With Adicet Bio - Technology Networks
Deal Watch: Lilly Teams With GPCR-Focused Superluminal In Cardiometabolic Disease - insights.citeline.com
Adicet Bio’s SWOT analysis: cell therapy firm’s stock faces clinical hurdles - Investing.com
Adicet Bio (ACET) Upgraded to Buy: Here's Why - MSN
Citizens JMP maintains Market Perform rating on Adicet Bio stock By Investing.com - Investing.com South Africa
Citizens JMP maintains Market Perform rating on Adicet Bio stock - Investing.com India
What makes Adicet Bio Inc. stock price move sharplyFree Top 5 Picks of the Week - thegnnews.com
What is the next catalyst for Adicet Bio Inc.Squeeze Play Stock Candidates - mustnews.co.kr
MaxCyte Signs Strategic Platform License with Adicet Bio for Cancer and Autoimmune Diseases Treatments. - AInvest
MaxCyte (MXCT) Signed a Strategic Platform License with Adicet Bio - Yahoo Finance
Adicet Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
MaxCyte signs platform license agreement with Adicet Bio for Gamma Delta T cell therapies - SelectScience
Layoff Tracker: Bicycle, Tune, Iovance, Precision Downsize to Conserve Cash - BioSpace
MaxCyte signs platform license agreement with Adicet Bio - MSN
JonesTrading Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
Adicet Bio Reports Q2 2025 Financial Results - The Globe and Mail
Adicet Bio: Strategic Advancements and Financial Prudence Drive Analyst's Buy Rating - AInvest
Adicet Bio: Strategic Advancements and Financial Prudence Drive Buy Rating - TipRanks
Adicet Bio Inc expected to post a loss of 32 cents a shareEarnings Preview - TradingView
Adicet Bio (ACET) Q2 Loss Widens 3% - AOL.com
Adicet Bio reports Q2 EPS (34c), consensus (30c) - TipRanks
Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference - BioSpace
MaxCyte Partners with Adicet Bio for Gamma Delta T Cell Therapy Platform License Agreement - AInvest
MaxCyte Inks Strategic Platform License with Adicet Bio, Entitled to Licensing Fees and Revenue - AInvest
Maxcyte signs platform license agreement with Adicet Bio - MarketScreener
MaxCyte Signs Platform License Agreement with Adicet Bio - The Manila Times
MaxCyte, Adicet Bio Sign Strategic Platform License Agreement - AInvest
MaxCyte Expands Cell Therapy Reach: Strategic License Deal Powers Adicet's Cancer Treatment Innovation - Stock Titan
What are Adicet Bio Inc. company’s key revenue driversAchieve rapid portfolio growth with smart picks - Jammu Links News
Is it the right time to buy Adicet Bio Inc. stockMaximize gains with proven stock analysis - Jammu Links News
What markets is Adicet Bio Inc. expanding into Is AMZE stock a good long term investment optionTriple-digit return opportunities - Jammu Links News
What drives Adicet Bio Inc. stock priceBuild a diversified portfolio for steady growth - Jammu Links News
Why is Adicet Bio Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Should I hold or sell Adicet Bio Inc. stock in 2025Unmatched profit potential - Jammu Links News
What is the risk reward ratio of investing in Adicet Bio Inc. stockFree Consultation - Jammu Links News
How does Adicet Bio Inc. compare to its industry peersFastest-growing stock picks - Jammu Links News
What institutional investors are buying Adicet Bio Inc. stockNavigate the market with precision tools - Jammu Links News
Is Adicet Bio Inc. stock overvalued or undervaluedBuild wealth with steady, reliable stocks - Jammu Links News
When is Adicet Bio Inc. stock expected to show significant growthFastest return on investment - Jammu Links News
How does Adicet Bio Inc. generate profit in a changing economyMarket-crushing profits - Jammu Links News
What are the technical indicators suggesting about Adicet Bio Inc.Track top-performing stocks effortlessly - Jammu Links News
Building trade automation scripts for Adicet Bio Inc.Low Exposure Strategy with Sector Analysis - Newser
How high can Adicet Bio Inc. stock price go in 2025Free Daily Momentum Screener With Alerts - Newser
Tools to monitor Adicet Bio Inc. recovery probabilityPattern Recognition Tool for ROI Investors - Newser
Sentiment analysis tools applied to Adicet Bio Inc.AI Enhanced Strategy for Portfolio Growth - Newser
Pattern recognition hints at Adicet Bio Inc. upsideBreakout Screener With Alert Based Timing - Newser
Custom watchlist performance reports with Adicet Bio Inc.Predictable Return Plan with Entry Guidance - Newser
Adicet Bio Inc (ACET) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.88%
자본화:
|
볼륨(24시간):